IN2014DN01993A - - Google Patents
Info
- Publication number
- IN2014DN01993A IN2014DN01993A IN1993DEN2014A IN2014DN01993A IN 2014DN01993 A IN2014DN01993 A IN 2014DN01993A IN 1993DEN2014 A IN1993DEN2014 A IN 1993DEN2014A IN 2014DN01993 A IN2014DN01993 A IN 2014DN01993A
- Authority
- IN
- India
- Prior art keywords
- methyl
- aminosulfonyl
- thiazol
- pyridinyl
- phenyl
- Prior art date
Links
- ZZLCFHIKESPLTH-UHFFFAOYSA-N 4-Methylbiphenyl Chemical compound C1=CC(C)=CC=C1C1=CC=CC=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- OIXMUQLVDNPHNS-UHFFFAOYSA-N methanesulfonic acid;hydrate Chemical compound O.CS(O)(=O)=O OIXMUQLVDNPHNS-UHFFFAOYSA-N 0.000 abstract 2
- FCVMHSMWASHTGN-UHFFFAOYSA-N n-methyl-2-(4-pyridin-2-ylphenyl)acetamide Chemical compound C1=CC(CC(=O)NC)=CC=C1C1=CC=CC=N1 FCVMHSMWASHTGN-UHFFFAOYSA-N 0.000 abstract 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 abstract 2
- HBXRPXYBMZDIQL-UHFFFAOYSA-N 1$l^{2}-borolane Chemical compound [B]1CCCC1 HBXRPXYBMZDIQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001642 boronic acid derivatives Chemical class 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 150000003606 tin compounds Chemical class 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11007823A EP2573086A1 (en) | 2011-09-26 | 2011-09-26 | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| PCT/EP2012/068938 WO2013045479A1 (en) | 2011-09-26 | 2012-09-26 | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01993A true IN2014DN01993A (OSRAM) | 2015-05-15 |
Family
ID=46889067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1993DEN2014 IN2014DN01993A (OSRAM) | 2011-09-26 | 2012-09-26 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9340535B2 (OSRAM) |
| EP (3) | EP2573086A1 (OSRAM) |
| JP (2) | JP6161614B2 (OSRAM) |
| KR (4) | KR20190104249A (OSRAM) |
| CN (2) | CN105541829A (OSRAM) |
| AR (3) | AR088043A1 (OSRAM) |
| AU (2) | AU2012314536B2 (OSRAM) |
| BR (1) | BR112014003245B1 (OSRAM) |
| CA (1) | CA2791142C (OSRAM) |
| CL (1) | CL2014000149A1 (OSRAM) |
| DK (2) | DK2598501T3 (OSRAM) |
| ES (2) | ES2466221T3 (OSRAM) |
| HK (1) | HK1220978A1 (OSRAM) |
| HR (1) | HRP20140351T1 (OSRAM) |
| IL (2) | IL230152A (OSRAM) |
| IN (1) | IN2014DN01993A (OSRAM) |
| JO (2) | JO3037B1 (OSRAM) |
| MX (2) | MX371088B (OSRAM) |
| MY (2) | MY190878A (OSRAM) |
| PE (1) | PE20141148A1 (OSRAM) |
| PH (2) | PH12014500567A1 (OSRAM) |
| PL (2) | PL2598501T3 (OSRAM) |
| PT (1) | PT2598501E (OSRAM) |
| RU (2) | RU2669388C1 (OSRAM) |
| SG (1) | SG10201407430TA (OSRAM) |
| TW (2) | TWI567070B (OSRAM) |
| UA (2) | UA115317C2 (OSRAM) |
| WO (1) | WO2013045479A1 (OSRAM) |
| ZA (2) | ZA201401773B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| CR20180482A (es) * | 2016-04-06 | 2019-04-09 | Innovative Molecules Gmbh | Derivados de aminotiazol útiles como agentes antivíricos |
| PT3848369T (pt) * | 2016-11-28 | 2023-04-10 | Aicuris Gmbh & Co Kg | Hemi-hidrato da base livre de n-[5-(aminossulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricação e suas utilizações |
| WO2018096177A1 (en) * | 2016-11-28 | 2018-05-31 | Aicuris Anti-Infective Cures Gmbh | A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses |
| TW201825095A (zh) * | 2016-11-28 | 2018-07-16 | 德商艾庫里斯抗感染治療有限公司 | 包含n-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之局部醫藥調配物 |
| KR102335327B1 (ko) | 2017-04-28 | 2021-12-03 | 현대자동차 주식회사 | 수냉식 이지알 쿨러 |
| EP3644958B1 (en) * | 2017-06-28 | 2021-09-29 | AiCuris GmbH & Co. KG | Intravaginally applicable devices comprising antiviral compounds |
| AR113344A1 (es) | 2017-10-05 | 2020-04-22 | Innovative Molecules Gmbh | Enantiómeros de una serie de compuestos antivirales |
| KR102535452B1 (ko) | 2018-07-06 | 2023-05-26 | 파에노 테라퓨틱스 씨오., 엘티디. | 티아졸 화합물의 결정형 및 이의 응용 |
| EP4509118A3 (en) * | 2018-09-19 | 2025-05-14 | ModernaTX, Inc. | High-purity peg lipids and uses thereof |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| EP4096632A1 (en) * | 2020-03-26 | 2022-12-07 | AiCuris GmbH & Co. KG | Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate |
| EP4581030A1 (en) | 2022-08-29 | 2025-07-09 | Assembly Biosciences, Inc. | A novel crystalline form of pritelivir |
| CN119731171A (zh) | 2022-08-29 | 2025-03-28 | 组装生物科学股份有限公司 | 普瑞利韦的新的结晶形式 |
| JP2025530762A (ja) | 2022-08-29 | 2025-09-17 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | ヘルペスウイルス用医薬組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10129716A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129717A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129714A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) * | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| JP2007314516A (ja) * | 2006-04-25 | 2007-12-06 | Daiichi Sankyo Co Ltd | ２以上の置換基を有するベンゼン化合物を含有する医薬 |
| EA201200423A1 (ru) * | 2006-06-09 | 2012-08-30 | Икос Корпорейшн | Замещенные фенилуксусные кислоты как dp-2-антагонисты |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2011
- 2011-09-26 EP EP11007823A patent/EP2573086A1/en not_active Withdrawn
-
2012
- 2012-09-21 TW TW105109173A patent/TWI567070B/zh active
- 2012-09-21 TW TW101134784A patent/TWI532739B/zh active
- 2012-09-23 JO JOP/2012/0276A patent/JO3037B1/ar active
- 2012-09-26 RU RU2017114501A patent/RU2669388C1/ru active
- 2012-09-26 MX MX2015016192A patent/MX371088B/es unknown
- 2012-09-26 KR KR1020197025387A patent/KR20190104249A/ko not_active Ceased
- 2012-09-26 MY MYPI2017702805A patent/MY190878A/en unknown
- 2012-09-26 IN IN1993DEN2014 patent/IN2014DN01993A/en unknown
- 2012-09-26 PT PT127623007T patent/PT2598501E/pt unknown
- 2012-09-26 DK DK12762300.7T patent/DK2598501T3/da active
- 2012-09-26 RU RU2014107430A patent/RU2620604C2/ru active
- 2012-09-26 BR BR112014003245-9A patent/BR112014003245B1/pt active IP Right Grant
- 2012-09-26 SG SG10201407430TA patent/SG10201407430TA/en unknown
- 2012-09-26 AR ARP120103551A patent/AR088043A1/es not_active Application Discontinuation
- 2012-09-26 PE PE2014000390A patent/PE20141148A1/es active IP Right Grant
- 2012-09-26 CA CA2791142A patent/CA2791142C/en active Active
- 2012-09-26 UA UAA201404411A patent/UA115317C2/uk unknown
- 2012-09-26 US US14/347,287 patent/US9340535B2/en active Active
- 2012-09-26 DK DK13157396.6T patent/DK2602258T3/da active
- 2012-09-26 CN CN201511005819.8A patent/CN105541829A/zh active Pending
- 2012-09-26 CN CN201280046744.6A patent/CN103842359B/zh active Active
- 2012-09-26 MX MX2014003389A patent/MX338736B/es active IP Right Grant
- 2012-09-26 AU AU2012314536A patent/AU2012314536B2/en active Active
- 2012-09-26 JP JP2014532361A patent/JP6161614B2/ja active Active
- 2012-09-26 ES ES13157396.6T patent/ES2466221T3/es active Active
- 2012-09-26 HR HRP20140351AT patent/HRP20140351T1/hr unknown
- 2012-09-26 EP EP13157396.6A patent/EP2602258B8/en active Active
- 2012-09-26 KR KR1020177012548A patent/KR20170055565A/ko not_active Ceased
- 2012-09-26 KR KR1020187021891A patent/KR20180088530A/ko not_active Ceased
- 2012-09-26 UA UAA201704493A patent/UA119574C2/uk unknown
- 2012-09-26 EP EP12762300.7A patent/EP2598501B1/en active Active
- 2012-09-26 WO PCT/EP2012/068938 patent/WO2013045479A1/en not_active Ceased
- 2012-09-26 PL PL12762300T patent/PL2598501T3/pl unknown
- 2012-09-26 KR KR1020147004026A patent/KR101768295B1/ko active Active
- 2012-09-26 PL PL13157396T patent/PL2602258T3/pl unknown
- 2012-09-26 PH PH1/2014/500567A patent/PH12014500567A1/en unknown
- 2012-09-26 ES ES12762300.7T patent/ES2462492T3/es active Active
- 2012-09-26 MY MYPI2014000656A patent/MY185063A/en unknown
-
2013
- 2013-12-24 IL IL230152A patent/IL230152A/en active IP Right Grant
-
2014
- 2014-01-20 CL CL2014000149A patent/CL2014000149A1/es unknown
- 2014-03-11 ZA ZA2014/01773A patent/ZA201401773B/en unknown
- 2014-09-01 IL IL234405A patent/IL234405A/en active IP Right Grant
- 2014-09-02 HK HK16109165.2A patent/HK1220978A1/zh unknown
- 2014-11-27 ZA ZA2014/08734A patent/ZA201408734B/en unknown
-
2015
- 2015-11-24 AU AU2015260762A patent/AU2015260762B2/en active Active
- 2015-12-16 PH PH12015502801A patent/PH12015502801B1/en unknown
-
2016
- 2016-06-07 JO JOP/2016/0114A patent/JO3734B1/ar active
- 2016-12-22 JP JP2016249351A patent/JP6353022B2/ja active Active
-
2019
- 2019-09-13 AR ARP190102595A patent/AR116394A2/es not_active Application Discontinuation
-
2020
- 2020-10-23 AR ARP200102938A patent/AR120291A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01993A (OSRAM) | ||
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| PH12013501704A1 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| TN2011000400A1 (en) | Inhibitors of beta-secretase | |
| TN2016000210A1 (en) | Urea derivative or pharmacologically acceptable salt thereof. | |
| MY165087A (en) | Neprilysin inhibitors | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| MX348654B (es) | Composicion farmaceutica con biodisponibilidad mejorada para compuesto hidrofobico de alto punto de fusion. | |
| NZ707389A (en) | Process for preparing bile acid derivatives | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| IN2014CN04530A (OSRAM) | ||
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| MX338392B (es) | Cristal de derivado de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo. | |
| IN2014DN01992A (OSRAM) | ||
| ATE500222T1 (de) | Benzamid- und heteroarenderivate als cetp- inhibitoren | |
| CR20130501A (es) | Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| IN2014DN01629A (OSRAM) | ||
| MX2013006768A (es) | Moduladores de receptor de glucagon. | |
| MY149973A (en) | 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists | |
| PH12012000124A1 (en) | Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing it | |
| MX364529B (es) | Nuevos ligandos del receptor de estrógeno. | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| TW201612188A (en) | The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor |